Therametrics holding AG - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Therametrics holding AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Therametrics holding AG - Product Pipeline Review - 2014', provides an overview of the Therametrics holding AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Therametrics holding AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Therametrics holding AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Therametrics holding AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Therametrics holding AG's pipeline products

Reasons to buy

- Evaluate Therametrics holding AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Therametrics holding AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Therametrics holding AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Therametrics holding AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Therametrics holding AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Therametrics holding AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Therametrics holding AG Snapshot 6
Therametrics holding AG Overview 6
Key Information 6
Key Facts 6
Therametrics holding AG - Research and Development Overview 7
Key Therapeutic Areas 7
Therametrics holding AG - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Therametrics holding AG - Pipeline Products Glance 12
Therametrics holding AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Therametrics holding AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Therametrics holding AG - Drug Profiles 16
DasKloster-1000-01 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
DasKloster-1000-02 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
interferon gamma-1b 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
thymopentin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DasKloster-0141-01 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
DasKloster-0210-01 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DasKloster-1000-04 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DasKloster-0014-01 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DasKloster-0182-01 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DasKloster-0247-01 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DasKloster-0249-01 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DasKloster-0274-01 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
secretin 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DasKloster-0039-01 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DasKloster-0080-01 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DasKloster-0228-01 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DasKloster-0501-01 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Synthetic Peptides for Undisclosed Program 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Therametrics holding AG - Pipeline Analysis 36
Therametrics holding AG - Pipeline Products by Target 36
Therametrics holding AG - Pipeline Products by Route of Administration 37
Therametrics holding AG - Pipeline Products by Molecule Type 38
Therametrics holding AG - Pipeline Products by Mechanism of Action 39
Therametrics holding AG - Recent Pipeline Updates 40
Therametrics holding AG - Dormant Projects 43
Therametrics holding AG - Company Statement 44
Therametrics holding AG - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Therametrics holding AG, Key Information 6
Therametrics holding AG, Key Facts 6
Therametrics holding AG - Pipeline by Indication, 2014 9
Therametrics holding AG - Pipeline by Stage of Development, 2014 10
Therametrics holding AG - Monotherapy Products in Pipeline, 2014 11
Therametrics holding AG - Phase II, 2014 12
Therametrics holding AG - Phase I, 2014 13
Therametrics holding AG - Preclinical, 2014 14
Therametrics holding AG - Discovery, 2014 15
Therametrics holding AG - Pipeline by Target, 2014 36
Therametrics holding AG - Pipeline by Route of Administration, 2014 37
Therametrics holding AG - Pipeline by Molecule Type, 2014 38
Therametrics holding AG - Pipeline Products by Mechanism of Action, 2014 39
Therametrics holding AG - Recent Pipeline Updates, 2014 40
Therametrics holding AG - Dormant Developmental Projects,2014 43
Therametrics holding AG, Subsidiaries 46